Loading...
Docoh

Clearside Biomedical (CLSD)

Clearside Biomedical, Inc. is a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases. Clearside's proprietary SCS Microinjector® targets the suprachoroidal space (SCS®) and offers unique access to the macula, retina and choroid where sight-threatening disease often occurs. The Company's SCS injection platform is an inherently flexible, in-office, non-surgical procedure, intended to provide targeted delivery to the site of disease and to work with both established and new formulations of medications.

CLSD stock data

Analyst ratings and price targets

Last 3 months

Investment data

Data from SEC filings
Securities sold
Number of investors

Calendar

12 Aug 22
1 Oct 22
31 Dec 22
Quarter (USD) Jun 22 Mar 22 Dec 21 Sep 21
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD) Dec 21 Dec 20 Dec 19 Dec 18
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Cash burn rate (est.) Burn method: Change in cash Burn method: Operating income Burn method: FCF (opex + capex)
Last Q Avg 4Q Last Q Avg 4Q Last Q Avg 4Q
Cash on hand (at last report) 29.19M 29.19M 29.19M 29.19M 29.19M 29.19M
Cash burn (monthly) 1.81M (no burn) 2.61M 138.75K 1.81M (no burn)
Cash used (since last report) 5.55M n/a 7.99M 424.43K 5.55M n/a
Cash remaining 23.65M n/a 21.2M 28.77M 23.64M n/a
Runway (months of cash) 13.0 n/a 8.1 207.3 13.0 n/a

Beta Read what these cash burn values mean

Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
22 Jun 22 Thorp Clay Stock Option Common Stock Grant Acquire A No No 1.62 30,000 48.6K 30,000
22 Jun 22 Edwards Jeffrey L Stock Option Common Stock Grant Acquire A No No 1.62 30,000 48.6K 30,000
22 Jun 22 William D. Humphries Stock Option Common Stock Grant Acquire A No No 1.62 30,000 48.6K 30,000
22 Jun 22 Croarkin Richard Stock Option Common Stock Grant Acquire A No No 1.62 30,000 48.6K 30,000
22 Jun 22 Nancy J Hutson Stock Option Common Stock Grant Acquire A No No 1.62 30,000 48.6K 30,000
13F holders Current Prev Q Change
Total holders 56 61 -8.2%
Opened positions 6 9 -33.3%
Closed positions 11 17 -35.3%
Increased positions 9 14 -35.7%
Reduced positions 25 22 +13.6%
13F shares Current Prev Q Change
Total value 46.74M 43.95M +6.3%
Total shares 16.05M 18.72M -14.2%
Total puts 188.4K 173.1K +8.8%
Total calls 83.4K 75.6K +10.3%
Total put/call ratio 2.3 2.3 -1.3%
Largest owners Shares Value Change
Carmignac Gestion 2.39M $3.51M -3.8%
Whitmore Bradford T 2.35M $6.46M 0.0%
ACT Capital Management, LLLP 2.29M $3.36M -6.9%
Vanguard 2.17M $3.18M 0.0%
BLK Blackrock 1.21M $1.78M -0.5%
Renaissance Technologies 807.79K $1.19M -6.6%
Assenagon Asset Management 756.2K $1.11M -17.2%
MS Morgan Stanley 601.73K $885K -47.3%
Geode Capital Management 523.99K $770K +7.0%
Two Sigma Advisers 361.9K $532K -45.0%
Largest transactions Shares Bought/sold Change
Millennium Management 305.72K -755.2K -71.2%
MS Morgan Stanley 601.73K -540.11K -47.3%
Two Sigma Advisers 361.9K -296.4K -45.0%
Marshall Wace 217.82K -194.22K -47.1%
ACT Capital Management, LLLP 2.29M -170.4K -6.9%
Assenagon Asset Management 756.2K -157.59K -17.2%
Two Sigma Investments 211.89K -122.62K -36.7%
Carmignac Gestion 2.39M -95.31K -3.8%
Jane Street 0 -86.22K EXIT
Susquehanna International 167.41K +63.57K +61.2%

Financial report summary

?

Content analysis

?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. junior Avg
New words: assuming, attainment, authorized, automatically, avoidance, cap, cease, Closing, comply, Emory, escrow, failure, foreclose, foreclosure, guaranty, HCR, headcount, HealthCare, indemnification, maintenance, Meeting, pledge, recourse, released, return, subsidiary, Tech, Threshold, University, violate, violated, virtue
Removed: decreased